Lawrence F. Eichenfield, MD In this presentation, Dr Eichenfield discusses inflammatory diseases in children in a clinically relevant manner. Dr Eichenfield provides a review of the pathogenesis of atopic dermatitis (AD), the role of filaggrin, and allergies in AD. He also updated us on new findings in pediatric psoriasis. Atopic Dermatitis (AD) When reviewing AD, […]
Ted Rosen, MD & Neal Bhatia, MD Imiquimod for Actinic Keratosis There are three doses of imiquimod: 5%. 3.75% and the new 2.5% (which is approved, but not commercially available at this point). What are their uses? Where does the 2.5% fit in? According to Dr Bhatia: 5% for solid tumors or more aggressive fields? […]
Ted Rosen, MD & Neal Bhatia, MD New Treatment for Orolabial Herpes Acyclovir 5% + Hydrocortisone 1% This is a cream formulation that was approved in late 2009. It is designed to supplement the anti-viral effect of acyclovir with an anti-inflammatory effect of hydrocortisone. Inflammation may be responsible for some of the signs/symptoms of HSV-1. […]
Keith Flaherty, MD & George Martin, MD Vismodegib (ErivedgeTM) for the Treatment of Advanced Basal Cell Carcinoma (BCC) Dr Keith Flaherty, an oncologist at MGH, spoke on ErivedgeTM for the treatment of advanced and metastatic BCC. Historically, the treatment of patients with advanced BCC with either metastatic or locally advanced disease employed standard chemotherapeutic regimens […]
Keith Flaherty, MD & George Martin, MD The hot topics of discussion at Maui Derm 2012 were January’s FDA approval of two innovative products in the cutaneous oncology arena: (Picato®), ingenol mebutate 0.015% gel and 0.05% gel for the treatment of actinic keratoses (AKs) and Erivedge® (vismodegib) for the treatment of advanced basal cell carcinoma. […]
Bruce Strober, MD, PhD In this presentation, Dr Strober discusses the important concept of immunogenicity as it relates to the management of psoriasis and the use of biologic therapy. There are several factors that lead to the loss of therapeutic response. These factors include drug level reduction, specifically immunogenicity, suboptimal dosing schedules (e.g. etanercept step-down […]
Sheila Friedlander, Ilona Freiden Diaper Rashes 1984 was the introduction of a superabsorbent polymer, sodium polyacrylate. It absorbs a lot of water and converts from powder to gel. These diapers also buffer pH, they have a polyethylene film surface, are less irritant, and are better at containing fecal bacteria. The lesions for diaper rash tend […]
Sheila Friedlander, MD and Ilona Frieden, MD What’s really new in pediatric dermatology? In this presentation, Drs. Friedlander and Frieden discussed the latest and greatest in pediatric dermatology. Beta Blockers & Hemangiomas Do hemangiomas go away? Before 2008 and to this day, many treatments can provide modest efficacy, and are best used in growth […]
Dale Westrom, MD, PhD Why did Dr. Westrom start his walk-in clinic? In 2007, Dr. Westrom read an article by Jack Resneck stating that it was easier to see a dermatologist for Botox® than a changing mole. Dr. Westrom who felt that the article reflected very poorly on our profession took this article very seriously. […]
Panelists: James Del Rosso, MD, Alan Shalita, MD, Guy Webster, MD, PhD For decades the pathogenesis of acne has centered on the formation of the microcomedones as the initiating event followed by an inflammatory cascade. This dogma is now being questioned in a “chicken vs. egg” scenario as being raised as to whether the microcomedone […]
Administrative Office
Maui Derm
161 Wailea Ike Place, Suite A-104
Kihei, HI 96753
Stay Connected
Sign up to receive updates about upcoming meetings.